While T-VEC has provided another option for patients with melanoma, the integration of T-VEC into clinical practice occurred at a time of unprecedented therapeutic advances in melanoma, including the approval of BRAF/EK targeted therapy and single agents as well as combination immune checkpoint blockade (Luke et al., 2017). This evidence concerns the gene BRAF and melanoma.